- TIBSOVO Demonstrated a Statistically Significant Improvement in Progression-Free Survival Compared to Placebo -
- Safety Profile Consistent with Published Phase 1 Data in Patients with IDH1 Mutant Solid Tumors -
- Supplemental New Drug Application on Track for Submission by End of 2019 -
PR Newswire
SUZHOU, China, May 23, 2019